ORGOVYX

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Estonia, France, Ireland, Italy, Lithuania, Romania, Spain.

Active ingredients

The drug ORGOVYX contains one active pharmaceutical ingredient (API):

1	Relugolix UNII P76B05O5V6 - RELUGOLIX
	Relugolix is a nonpeptide GnRH receptor antagonist that competitively binds to GnRH receptors in the anterior pituitary gland preventing native GnRH from binding and signalling the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Consequently, the production of testosterone from the testes is reduced.
	Read more about Relugolix

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ORGOVYX Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)
ORGOVYX Film-coated tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L02BX04		L Antineoplastic and immunomodulating agents → L02 Endocrine therapy → L02B Hormone antagonists and related agents → L02BX Other hormone antagonists and related agents
Discover more medicines within L02BX04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1883134
ES	Centro de información online de medicamentos de la AEMPS	1221642001
FR	Base de données publique des médicaments	65083759
IT	Agenzia del Farmaco	050079019, 050079021
LT	Valstybinė vaistų kontrolės tarnyba	1094667, 1096914
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W69487001
US	FDA, National Drug Code	72974-120